Currently, the most promising inhibitor targeting the NDC80/NUF2 pathway is INH11, which disrupts the formation of Ndc80–NUF2 complex, has been shown to reduce proliferation in breast cancer cells and reduce tumour growth in a xenograft mouse model [31]. Here, NDC80 is linked to breast cancer.